Stocklytics Platform
Asset logo for symbol SCYX
SCYNEXIS
SCYX95
$2.11arrow_drop_up1.19%$0.02
High Value
High Quality
Penny Stock
Asset logo for symbol SCYX
SCYX95

$2.11

arrow_drop_up1.19%

Performance History

Chart placeholder
Key Stats
Open$2.11
Prev. Close$2.08
EPS2.11
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$80.09M
LOWHIGH
Day Range2.09
2.14
52 Week Range1.35
3.87
Ratios
Revenue-
EPS2.11

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Correlated Companies

Asset logo for symbol LLY
Eli Lilly & Co
LLY74
Price$805.15
Perf. (24h)
arrow_drop_down1.95%-$16.03
Market Cap$738.87B
Asset logo for symbol UNH
UnitedHealth Group
UNH71
Price$570.00
Perf. (24h)
arrow_drop_up1.84%$10.32
Market Cap$527.83B
Asset logo for symbol JNJ
Johnson & Johnson
JNJ62
Price$160.66
Perf. (24h)
arrow_drop_up0.63%$1.02
Market Cap$382.01B
Asset logo for symbol ABBV
AbbVie
ABBV62
Price$185.19
Perf. (24h)
arrow_drop_up1.65%$3.02
Market Cap$326.96B

About SCYNEXIS (SCYX)

SCYNEXIS Inc (SCYX) is a biotechnology company that focuses on the discovery, development, and commercialization of novel anti-infectives to address unmet needs in the treatment of infectious diseases. The company's lead product candidate is ibrexafungerp (formerly known as SCY-078), a novel oral and intravenous (IV) antifungal agent that is being developed for the treatment of fungal infections, including vulvovaginal candidiasis (VVC) and invasive candidiasis. This innovative drug has the potential to become a first-line treatment option for patients suffering from these debilitating infections. With its broad-spectrum antifungal activity and favorable safety profile, ibrexafungerp has generated significant interest within the medical community and pharmaceutical industry.
The historical stock price of SCYNEXIS Inc (SCYX) has shown some volatility, but overall, the company has demonstrated steady growth. Over the past five years, the stock price has experienced fluctuations, reaching a high of $18.54 per share in March 2018 and a low of $2.36 per share in February 2021. Despite these fluctuations, SCYNEXIS has managed to maintain a strong market position and attract investor interest. The company's market capitalization currently stands at around $300 million, reflecting the market's confidence in SCYNEXIS's potential for growth and success in the biopharmaceutical industry.
Websitecall_made
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
CEO
Mr. David Gonzalez Angulo M.D.
Headquarters
Jersey City
Employees
36
Exchange
NASDAQ
add SCYNEXIS to watchlist

Keep an eye on SCYNEXIS

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is SCYNEXIS 's (SCYX) price per share?
The current price per share for SCYNEXIS (SCYX) is $2.11. The stock has seen a price change of $0.02 recently, indicating a 1.2% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for SCYNEXIS (SCYX)?
For SCYNEXIS (SCYX), the 52-week high is $3.87, which is 83.41% from the current price. The 52-week low is $1.35, the current price is 56.3% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is SCYNEXIS (SCYX) a growth stock?
SCYNEXIS (SCYX) has shown an average price growth of 0.41% over the past three years. It has received a score of 17 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying SCYNEXIS as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is SCYNEXIS (SCYX) stock price performance year to date (YTD)?
As of the latest data, SCYNEXIS (SCYX) has a year-to-date price change of -4.52%. Over the past month, the stock has experienced a price change of 4.98%. Over the last three months, the change has been 37.01%. Over the past six months, the figure is 13.44%. Looking at a longer horizon, the five-year price change stands at -81.73%.
help
Is SCYNEXIS (SCYX) a profitable company?
SCYNEXIS (SCYX) has a net income of $67.04M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 88.27% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -692.5% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $123.71M. Operating income is noted at $72.67M. Furthermore, the EBITDA is $74.21M.
help
What is the market capitalization of SCYNEXIS (SCYX)?
SCYNEXIS (SCYX) has a market capitalization of $80.09M. The average daily trading volume is 110.25K, indicating the stock's liquidity and investor engagement.

News

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
EARNINGS RELEASES AND OPERATING RESULTS
5/8/2024

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
PRODUCT / SERVICES ANNOUNCEMENT
CALENDAR OF EVENTS
4/30/2024

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
CALENDAR OF EVENTS
4/9/2024

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
EARNINGS RELEASES AND OPERATING RESULTS
3/28/2024

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
CALENDAR OF EVENTS
1/30/2024

SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
PRODUCT / SERVICES ANNOUNCEMENT
1/29/2024

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level